Latest News for: map kinase

Edit

Poolbeg Pharma plc – POLB 001 Patent Granted in Korea

Pharmiweb 20 Mar 2025
POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) and severe influenza.
  • 1
×